Furthermore, the inhibitor (ipilimumab) for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which suppresses immune responses, has been approved for treating NSCLC [5] and some other cancers [7]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.